Literature DB >> 17119846

Determinants of health related quality of life and health state utility in patients with age related macular degeneration: the association of contrast sensitivity and visual acuity.

N Bansback1, C Czoski-Murray, J Carlton, G Lewis, L Hughes, M Espallargues, C Brand, J Brazier.   

Abstract

BACKGROUND: There has been increasing interest in the use of measures of health related quality of life (HRQoL) and health state utility values in Age Related Macular Degeneration (ARMD). Visual acuity has been found to be an important determinant of such measures in previous studies. More recently, another measure of visual impairment, contrast sensitivity has received considerable attention. We designed a study to examine whether the contribution of contrast sensitivity in explaining HRQoL and health utilities over and above that of visual acuity.
METHODS: 209 patients with unilateral or bilateral ARMD were recruited into a cross-sectional study of patients from a large teaching hospital. Patients underwent visual tests (near and distant visual acuity, contrast sensitivity) and completed a vision function questionnaire, the VF-14, HUI3, and time trade-off.
RESULTS: Using multivariate regression analysis, the study revealed that contrast sensitivity remained a statistically significant predictor of all outcome measures even when visual acuity was included. This result was supported by the correlation coefficients between measures.
CONCLUSIONS: The measurement of contrast sensitivity appears to be better related to a person's HRQoL and health utility. Future studies should consider incorporating contrast sensitivity in addition to visual acuity. Studies, in particular economic evaluations, may underestimate the effect of treatment unless contrast sensitivity is considered.

Entities:  

Mesh:

Year:  2006        PMID: 17119846     DOI: 10.1007/s11136-006-9126-8

Source DB:  PubMed          Journal:  Qual Life Res        ISSN: 0962-9343            Impact factor:   4.147


  21 in total

1.  To what extent can we explain time trade-off values from other information about respondents?

Authors:  Paul Dolan; Jennifer Roberts
Journal:  Soc Sci Med       Date:  2002-03       Impact factor: 4.634

2.  Valuing health states: a comparison of methods.

Authors:  P Dolan; C Gudex; P Kind; A Williams
Journal:  J Health Econ       Date:  1996-04       Impact factor: 3.883

3.  Development of the 25-item National Eye Institute Visual Function Questionnaire.

Authors:  C M Mangione; P P Lee; P R Gutierrez; K Spritzer; S Berry; R D Hays
Journal:  Arch Ophthalmol       Date:  2001-07

4.  Utility values and age-related macular degeneration.

Authors:  G C Brown; S Sharma; M M Brown; J Kistler
Journal:  Arch Ophthalmol       Date:  2000-01

5.  Multiattribute and single-attribute utility functions for the health utilities index mark 3 system.

Authors:  David Feeny; William Furlong; George W Torrance; Charles H Goldsmith; Zenglong Zhu; Sonja DePauw; Margaret Denton; Michael Boyle
Journal:  Med Care       Date:  2002-02       Impact factor: 2.983

6.  Is the incidence of registrable age-related macular degeneration increasing?

Authors:  J Evans; R Wormald
Journal:  Br J Ophthalmol       Date:  1996-01       Impact factor: 4.638

7.  Aging and low-contrast vision: face perception.

Authors:  C Owsley; R Sekuler; C Boldt
Journal:  Invest Ophthalmol Vis Sci       Date:  1981-08       Impact factor: 4.799

8.  The design and use of a new near-vision chart.

Authors:  I L Bailey; J E Lovie
Journal:  Am J Optom Physiol Opt       Date:  1980-06

9.  Assessment of vision-related function in patients with age-related macular degeneration.

Authors:  Paul J Mackenzie; Tom S Chang; Ingrid U Scott; Mark Linder; Dawn Hay; William J Feuer; Keith Chambers
Journal:  Ophthalmology       Date:  2002-04       Impact factor: 12.079

10.  Reproducibility and responsiveness of the VF-14. An index of functional impairment in patients with cataracts.

Authors:  S D Cassard; D L Patrick; A M Damiano; M W Legro; J M Tielsch; M Diener-West; O D Schein; J C Javitt; E B Bass; E P Steinberg
Journal:  Arch Ophthalmol       Date:  1995-12
View more
  25 in total

1.  Functional changes following combined intravitreal bevacizumab and photodynamic therapy for polypoidal choroidal vasculopathy.

Authors:  Chengguo Zuo; Feng Wen; Jiaqing Li; Yan Liu; Shixian Long; Shizhou Huang; Meng Li
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2009-10-15       Impact factor: 3.117

2.  Comparison of vision-related quality of life in primary open-angle glaucoma and dry-type age-related macular degeneration.

Authors:  S Karadeniz Ugurlu; A E Kocakaya Altundal; M Altin Ekin
Journal:  Eye (Lond)       Date:  2016-11-04       Impact factor: 3.775

3.  Cost-effectiveness of autologous retinal pigment epithelium and choroid translocation in neovascular AMD.

Authors:  Aljoscha S Neubauer; Sandra Liakopoulos; Jan C van Meurs; Bernd Kirchhof
Journal:  Int J Ophthalmol       Date:  2010-09-18       Impact factor: 1.779

4.  Is the pediatric quality of life inventory valid for use in preschool children with refractive errors?

Authors:  Ecosse L Lamoureux; Manjula Marella; Benjamin Chang; Mohamed Dirani; Au Eong Kah-Guan; Audrey Chia; Terry L Young; Tien Y Wong; Seang Mei Saw
Journal:  Optom Vis Sci       Date:  2010-11       Impact factor: 1.973

5.  The impact of the severity of vision loss on vision-specific functioning in a German outpatient population - an observational study.

Authors:  Robert P Finger; Eva Fenwick; Peggy Pei-Chia Chiang; Michael Petrak; Frank G Holz; Manjula Marella; Ecosse L Lamoureux
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2011-04-05       Impact factor: 3.117

6.  Simulation Modelling in Ophthalmology: Application to Cost Effectiveness of Ranibizumab and Aflibercept for the Treatment of Wet Age-Related Macular Degeneration in the United Kingdom.

Authors:  Lindsay Claxton; Robert Hodgson; Matthew Taylor; Bill Malcolm; Ruth Pulikottil Jacob
Journal:  Pharmacoeconomics       Date:  2017-02       Impact factor: 4.981

7.  Quality of life in age-related macular degeneration: a review of available vision-specific psychometric tools.

Authors:  Robert P Finger; Monika Fleckenstein; Frank G Holz; Hendrik P N Scholl
Journal:  Qual Life Res       Date:  2008-05       Impact factor: 4.147

8.  Multilocus analysis of age-related macular degeneration.

Authors:  Julie Bergeron-Sawitzke; Bert Gold; Adam Olsh; Sarah Schlotterbeck; Kendal Lemon; Kala Visvanathan; Rando Allikmets; Michael Dean
Journal:  Eur J Hum Genet       Date:  2009-03-04       Impact factor: 4.246

9.  Simulation contact lenses for AMD health state utility values in NICE appraisals: a different reality.

Authors:  Thomas Butt; Michael D Crossland; Peter West; Shepley W Orr; Gary S Rubin
Journal:  Br J Ophthalmol       Date:  2014-10-28       Impact factor: 4.638

10.  The quality of life impact of peripheral versus central vision loss with a focus on glaucoma versus age-related macular degeneration.

Authors:  Keith Evans; Simon K Law; John Walt; Patricia Buchholz; Jan Hansen
Journal:  Clin Ophthalmol       Date:  2009-08-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.